Quick Answer
Liminatus Pharma, Inc. reported Stockholders Equity of -$9.81 million for the year ending 2025.
- Liminatus Pharma, Inc. showed an increase of +49.3% in Stockholders Equity from 2024 to 2025.
- This data is from Liminatus Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$17.55 million | Q2 2024: -$18.51 million | Q3 2024: -$19.11 million | Q1 2025: -$19.67 million | Q2 2025: -$8.81 million | Q3 2025: -$1.65 million.
- Over the full 3 years of available data (2023 to 2025), Liminatus Pharma, Inc.'s Stockholders Equity has grown by 37.9%.
- Historical annual values: Fiscal year 2025: -$9.81 million | Fiscal year 2024: -$19.34 million | Fiscal year 2023: -$15.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: